A PHASE 2 OPEN-LABEL STUDY TO ASSESS THE PHARMACODYNAMICS, PHARMACOKINETICS, SAFETY AND TOLERABILITY OF ISIS 703802 (AKCEA-ANGPTL3LRX) ADMINISTERED SUBCUTANEOUSLY TO PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)

Registry ID

ISIS 703802-CS4

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

PFIZER CANADA ULC

Start date

2018-03-29

Last update

2017-11-16

Conditions

• HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

Related clinical trials

• SAFETY AND EFFECTIVENESS OF EVINACUMAB FOR THE TREATMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN A REAL LIFE SETTING IN CANADA
• PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ARO-ANG3 IN SUBJECTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
• AN OPEN-LABEL LONG-TERM EXTENSION TO THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER, CROSS-OVER STUDY OF ROSUVASTATIN IN CHILDREN AND ADOLESCENTS (AGED 6 TO <18 YEARS) WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
• AN OPEN-LABEL, SINGLE-ARM, PROOF-OF-CONCEPT STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SINGLE AND MULTIPLE DOSES OF REGN1500 IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

View on source registry